X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare WYETH LTD with Biocon Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WYETH LTD vs BIOCON LTD - Comparison Results

WYETH LTD    Change

Wyeth Limited is the 51% subsidiary of Wyeth, US and is the sixth largest company among multinationals with revenues of Rs 2.9 bn in FY07. The company derives its revenues from pharmaceutical and OTC segments with focus on various therapeutic areas s... More

BIOCON LTD 
   Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WYETH LTD BIOCON LTD WYETH LTD/
BIOCON LTD
 
P/E (TTM) x 27.7 82.9 33.4% View Chart
P/BV x 5.3 7.8 68.6% View Chart
Dividend Yield % 1.3 0.2 801.2%  

Financials

 WYETH LTD   BIOCON LTD
EQUITY SHARE DATA
    WYETH LTD
Mar-13
BIOCON LTD
Mar-17
WYETH LTD/
BIOCON LTD
5-Yr Chart
Click to enlarge
High Rs1,0441,162 89.9%   
Low Rs818483 169.5%   
Sales per share (Unadj.) Rs298.6194.6 153.5%  
Earnings per share (Unadj.) Rs57.234.4 166.4%  
Cash flow per share (Unadj.) Rs58.448.3 121.0%  
Dividends per share (Unadj.) Rs17.001.00 1,700.0%  
Dividend yield (eoy) %1.80.1 1,501.0%  
Book value per share (Unadj.) Rs249.5241.9 103.1%  
Shares outstanding (eoy) m22.72200.00 11.4%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.14.2 73.8%   
Avg P/E ratio x16.323.9 68.1%  
P/CF ratio (eoy) x15.917.0 93.6%  
Price / Book Value ratio x3.73.4 109.8%  
Dividend payout %29.72.9 1,021.8%   
Avg Mkt Cap Rs m21,157164,440 12.9%   
No. of employees `0000.59.2 5.3%   
Total wages/salary Rs m4007,470 5.4%   
Avg. sales/employee Rs Th13,787.44,213.9 327.2%   
Avg. wages/employee Rs Th813.0809.0 100.5%   
Avg. net profit/employee Rs Th2,643.3745.2 354.7%   
INCOME DATA
Net Sales Rs m6,78338,911 17.4%  
Other income Rs m3531,571 22.4%   
Total revenues Rs m7,13640,482 17.6%   
Gross profit Rs m1,6179,795 16.5%  
Depreciation Rs m272,772 1.0%   
Interest Rs m6260 2.1%   
Profit before tax Rs m1,9388,334 23.3%   
Minority Interest Rs m0163 0.0%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-50-   
Tax Rs m6321,616 39.1%   
Profit after tax Rs m1,3016,881 18.9%  
Gross profit margin %23.825.2 94.7%  
Effective tax rate %32.619.4 168.3%   
Net profit margin %19.217.7 108.4%  
BALANCE SHEET DATA
Current assets Rs m6,98440,477 17.3%   
Current liabilities Rs m2,05616,783 12.2%   
Net working cap to sales %72.660.9 119.3%  
Current ratio x3.42.4 140.9%  
Inventory Days Days9960 166.6%  
Debtors Days Days2483 28.9%  
Net fixed assets Rs m24445,073 0.5%   
Share capital Rs m2271,000 22.7%   
"Free" reserves Rs m5,44147,377 11.5%   
Net worth Rs m5,66848,377 11.7%   
Long term debt Rs m2521,082 0.1%   
Total assets Rs m7,90193,942 8.4%  
Interest coverage x353.333.1 1,068.9%   
Debt to equity ratio x00.4 1.0%  
Sales to assets ratio x0.90.4 207.3%   
Return on assets %16.57.6 217.5%  
Return on equity %22.914.2 161.3%  
Return on capital %34.012.6 270.0%  
Exports to sales %0.20-   
Imports to sales %36.30-   
Exports (fob) Rs m15NA-   
Imports (cif) Rs m2,465NA-   
Fx inflow Rs m1512,988 0.1%   
Fx outflow Rs m2,6777,899 33.9%   
Net fx Rs m-2,6625,089 -52.3%   
CASH FLOW
From Operations Rs m9236,400 14.4%  
From Investments Rs m317-4,985 -6.4%  
From Financial Activity Rs m-481-1,775 27.1%  
Net Cashflow Rs m759-473 -160.5%  

Share Holding

Indian Promoters % 0.0 40.4 -  
Foreign collaborators % 51.1 20.6 248.1%  
Indian inst/Mut Fund % 11.3 8.4 134.5%  
FIIs % 7.2 10.7 67.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 30.4 19.9 152.8%  
Shareholders   21,978 109,995 20.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WYETH LTD With:   ASTRAZENECA PHARMA  DR. DATSONS LABS  CADILA HEALTHCARE  GSK PHARMA  PANACEA BIOTECH  

Compare WYETH LTD With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Stock Markets Chart Modest Gains(RoundUp)

Global financial markets ended the holiday shortened week with modest gains. The rally put behind days of decline as concerns regarding swift interest rates hikes were put to ease.

Related Views on News

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

The Foundation for Sensex 100,000 is Laid(The 5 Minute Wrapup)

Feb 17, 2018

Top three reasons for Tanushree's presentation at Equitymaster Conference to be centered around a possible 30% correction.

India's Rs 1,66,276 Crore Problem(Vivek Kaul's Diary)

Feb 15, 2018

That's the loss, the government owned public sector enterprises are expected to make this year.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

How I Beat the Index by 2x... And Why I Believe This Could Happen Again(Smart Contrarian)

Feb 12, 2018

Will Microcap Millionaires be able to replicate its past performance of beating the index by 2x?

NPAs Set to Rise Further with New RBI Rules(Chart Of The Day)

Feb 15, 2018

The RBI overhauls bad loan framework. Banks may come under additional pressure due to rising NPAs and increased provisioning.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

WYETH LTD SHARE PRICE


Dec 9, 2014 (Close)

TRACK WYETH LTD

  • Track your investment in WYETH LTD with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WYETH LTD 8-QTR ANALYSIS

COMPARE WYETH LTD WITH

MARKET STATS